All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma?

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Vincent Camus, Centre Henri-Becquerel, Rouen, FR. We asked, What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma (PMBL)?

What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma?

PMBL is a rare form of B-cell lymphoma mostly affecting younger female patients, and the optimal treatment for it is uncertain. Camus presents a large retrospective analysis, across Lymphoma Study Association (LYSA) centers, on patients with newly diagnosed PMBL. This analysis compared CHOP delivered every 21 days (CHOP21), CHOP delivered every 14 days (CHOP14), and ACVBP, all combined with rituximab.

Share: